515179-19-8

Basic information

• Product Name: (1R,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid
• CAS NO: 515179-19-8
• Molecular Weight: 180.179
• Mol File: 515179-19-8.mol
• Article Data: 26

Chemical Properties

• CAS DataBase Reference: (1R,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid(515179-19-8)
• EPA Substance Registry System: (1R,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid(515179-19-8)

Safety Data

• Hazardous Substances Data: 515179-19-8(Hazardous Substances Data)

Usage

General Description

(1R,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid is a chemical compound with a cyclopropane ring structure and a carboxylic acid functional group. It is a chiral compound, meaning it has two non-superimposable mirror image forms. The presence of the 4-fluorophenyl group in the molecule makes it useful for pharmaceutical applications as it can potentially interact with biological targets. (1R,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid can be used as a building block in the synthesis of pharmaceuticals or as a reference standard in analytical chemistry. Its unique structural and stereochemical properties make it a potential candidate for drug development and chemical research.

Upstream product

• 893751-08-1 trans-methyl 2-(4-fluorophenyl)cyclopropanecarboxylate 
• 214360-58-4 2-(4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1759-53-1 cyclopropanecarboxylic acid 
• 352-34-1 4-fluoro-1-iodobenzene 
• 623-73-4 diazoacetic acid ethyl ester 
• 405-99-2 para-fluorostyrene 
• 243665-10-3 (E)-3-(4-fluorophenyl)-N-methoxy-N-methylacrylamide 
• 893751-08-1 methyl 2-(4-fluorophenyl)cyclopropane-1-carboxylate 
• 459-32-5 (E)-4-fluorocinnamic acid 
• 96426-60-7 methyl (2E)-3-(4-fluorophenyl)-2-propenoate 
• 113903-98-3 tert-butyl 4-fluorocinnamate 
• 459-57-4 4-fluorobenzaldehyde 
• 459-32-5 4-fluorocinnamic acid 
• 301861-15-4 (+/-)-cis-2-(4-fluorophenyl)cyclopropanecarbonitrile 

Downstream Products

• 161711-27-9 (1R,2R)-2-(4-fluorophenyl)cyclopropanecarboxylic acid 
• 1414775-42-0 (1R,2R)-2-(4-fluorophenyl)cyclopropanecarboxylic acid [(R)-cyclopropyl-(3-ethanesulfonylphenyl)methyl](6-trifluoromethylpyridin-3-ylmethyl)amide 
• 1414775-44-2 (1R,2R)-2-(4-fluorophenyl)cyclopropanecarboxylic acid [(S)-cyclopropyl-(3-ethanesulfonylphenyl)methyl](6-trifluoromethylpyridin-3-ylmethyl)amide 
• 515179-19-8 (+)-(1S,2S)-2-(4-fluorophenyl)cyclopropanecarboxylic acid 
• 1314323-96-0 (1R,2S)-tert-butyl 2-(4-fluorophenyl)cyclopropylcarbamate 
• 113516-71-5 (1R,2S)-2-(4-fluorophenyl)cyclopropan-1-amine 
• 1609030-98-9 2-(4-fluorophenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)cyclopropane-1-carboxamide 

Relevant articles and documents

Co(II)-salen catalyzed stereoselective cyclopropanation of fluorinated styrenes

Three cis-selective Co(II)-salen complexes have been developed for the asymmetric cyclopropanation of para-fluorinated styrenes with ethyl diazoacetate. Increasing the steric reach of the C2-symmetric ligand side chains improved the enantiomeric ratio of the reaction from 28:1 to 66:1. The methodology was exemplified by the gram-scale synthesis of a lead compound for the treatment of castration-resistant prostate cancer (CRPC), as well as a structurally related analog.

PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS

The invention includes procedures for stereoselective β-arylation of carboxylic acids having a β-carbon atom. For example, stereoselective arylation procedures include the following reactions: (I)

Synthesis and in vitro evaluation of novel N-cycloalkylcarbamates as potential cholinesterase inhibitors

Abstract: This present paper describes the preparation and characterization of a series of O-substituted N-cycloalkylcarbamate derivatives. These compounds were tested as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). All studied carbamates exhibited moderate inhibitory activity of both cholinesterases with values of IC50 in the range of 36.1–78.6?μM for AChE and 9.8–215.4?μM for BChE, respectively. These values are comparable with those values of inhibition obtained with the established drug rivastigmine. The cytotoxicity of all carbamates was evaluated using standard in vitro test with Jurkat cells. Many of the studied carbamates can be considered as promising compounds for potential medicinal applications with regard to their inhibitory activity as well as negligible cytotoxicity.